SOURCE: Delphi Medical Systems

May 06, 2008 08:30 ET

New Delphi Portable Oxygen Concentrator Designed to Provide Exceptional Portability to Patients

TROY, MI--(Marketwire - May 6, 2008) - Delphi Corp. (PINKSHEETS: DPHIQ)

--  Lightweight device has the smallest footprint and package size in its
--  Innovative technology provides enhanced durability, oxygen volume and
    breath detection;
--  Agreement with evo secures distribution in North America

Today Delphi Medical Systems, a subsidiary of Delphi Corp. (PINKSHEETS: DPHIQ), is introducing its new portable oxygen concentrator, the Central Air, which can help patients gain increased freedom and independence by providing exceptional durability in a lightweight package. Delphi also announced that it has entered an exclusive agreement with evo Medical Solutions to distribute the device in North America for millions of adults who require supplemental oxygen treatment after being diagnosed with chronic obstructive pulmonary disease (COPD). Currently, the device has 510(k) clearance from the U.S. Food and Drug Administration (FDA).

Delphi's design delivers concentrated oxygen in a compact size and convenient format, and boasts the smallest footprint and package size in its class. Measuring under a foot high and weighing less than 10 pounds, the unit allows premium portability so that patients can participate in more mobile lifestyles.

"Delphi has a rich heritage of high-quality engineering and advanced technology capabilities in both automotive and medical products," said Francisco A. (Frank) Ordoñez, president, Delphi Product & Service Solutions. "This is a great opportunity for us to help bring portable oxygen concentrators into the mainstream with the level of reliability, quality and durability on which Delphi has built its reputation."

"Medical research increasingly demonstrates that people can lead longer, healthier lives and reduce their healthcare costs if they're able to maintain an active lifestyle," said Dave Berge, managing director, Delphi Medical Systems. "The Central Air allows a significant number of patients to get back to the activities of daily living, including work, recreation and moderate exercise, as recommended by their doctor."

The unit features a patented Delphi process that separates oxygen from room air using a unique PSA (pressure swing adsorption) cycle made practical for the first time with the use of Delphi's advanced electronics control capabilities. This design results in improved durability and innovative package size. Delphi's exclusive rotary compressor technology and design also enables the device to operate with less vibration than conventional compressors. Plus, Delphi's exclusive lightweight compressor has a design life greater than any compressors used in competitive products.

Whether at home or on-the-go, the device contains several options for power so that users can conveniently access oxygen from most locations. It can be powered by the included conventional AC power supply or rechargeable battery, or via DC power, such as an automotive 12-volt power receptacle.

Included accessories, such as a carrying case and pull cart, increase the device's versatility and allow patients to move around more readily by providing a means for safe and easy transport. The carrying case features a shoulder strap, a fabric enclosure and a clear protective cover that allows access to the control panel. With the Delphi custom fold-up cart, which features large easy-roll wheels, users can simply pull the concentrator along wherever they go.

The Central Air is available now and will be distributed in the U.S. exclusively through evo Medical Solutions' nationwide network. evo's president, Dan Bunting, says, "Delphi has re-defined the portable oxygen market with this landmark product. We have serviced the home health respiratory market for many years, and this industry has never had a device manufacturer with the size, depth, experience and innovation of a world player like Delphi. We are eager to bring this life-changing device to our customers for their COPD patients."

"evo's commitment to the pursuit of technology and equipment that will help patients live a more free and active lifestyle makes this partnership ideal," said Berge. "Together with evo, Delphi will be able to provide patients with a new, flexible option for oxygen therapy."

evo, a manufacturer and distributor of respiratory products, is based in Iowa and serves the home health market in the U.S. and abroad.

About Delphi Medical Systems

Delphi Medical Systems is a world-class provider of technology, products, and product development and manufacturing for Infusion, Respiratory Care, Vital Signs Monitoring and Power Mobility. Its capabilities stem from Delphi's vast technology base, product development expertise and manufacturing excellence. Delphi Medical Systems, Inc. is a wholly owned subsidiary of Delphi Automotive Systems, LLC and is part of Delphi Product and Service Solutions. For more information about Delphi Medical Systems, visit


This press release, including the exhibits being furnished as part of this report, as well as other statements made by Delphi may contain forward-looking statements that reflect, when made, the Company's current views with respect to current events and financial performance. Such forward-looking statements are and will be, as the case may be, subject to many risks, uncertainties and factors relating to the Company's operations and business environment which may cause the actual results of the Company to be materially different from any future results, express or implied, by such forward-looking statements. In some cases, you can identify these statements by forward-looking words such as "may," "might," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "potential" or "continue," the negative of these terms and other comparable terminology. Factors that could cause actual results to differ materially from these forward-looking statements include, but are not limited to, the following: the ability of the Company to continue as a going concern; the ability of the Company to operate pursuant to the terms of the debtor-in-possession financing facility, to obtain an extension of term or other amendments as necessary to maintain access to such facility and to secure the anticipated advances from GM in order to obtain any such extension or amendment; the Company's ability to obtain Court approval with respect to motions in the chapter 11 cases prosecuted by it from time to time; the ability of the Company to consummate its amended plan of reorganization which was confirmed by the Court on January 25, 2008 or any other subsequently confirmed plan of reorganization; risks associated with third parties seeking and obtaining Court approval to terminate or shorten the exclusivity period for the Company to propose and confirm one or more plans of reorganization, for the appointment of a chapter 11 trustee or to convert the cases to chapter 7 cases; the ability of the Company to obtain and maintain normal terms with vendors and service providers; the Company's ability to maintain contracts that are critical to its operations; the potential adverse impact of the chapter 11 cases on the Company's liquidity or results of operations; the ability of the Company to fund and execute its business plan (including the transformation plan described in Item 1. Business "Plan of Reorganization and Transformation Plan" of the Annual Report on Form 10-K for the year ended December 31, 2007 filed with the SEC) and to do so in a timely manner; the ability of the Company to attract, motivate and/or retain key executives and associates; the ability of the Company to avoid or continue to operate during a strike, or partial work stoppage or slow down by any of its unionized employees or those of its principal customers and the ability of the Company to attract and retain customers. Additional factors that could affect future results are identified in the Annual Report on Form 10-K for the year ended December 31, 2007 filed with the SEC, including the risk factors in Part I. Item 1A. Risk Factors, contained therein. Delphi disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events and/or otherwise. Similarly, these and other factors, including the terms of any reorganization plan ultimately confirmed, can affect the value of the Company's various prepetition liabilities, common stock and/or other equity securities.

Contact Information